Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study
Cancer Communications · 2024-09 · 44 (9) · 992-1004
DOI: 10.1002/cac2.12593 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Communications, online erschienen am 17.07.2024. Verfasst von Lin Li und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and…. Hauptthemen laut MEDLINE: Anaplastic Lymphoma Kinase, Carcinoma, Non-Small-Cell Lung, Gene Rearrangement, Lung Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CAMS Innovation Fund for Medical Sciences, Beijing Hope Run Special Fund of Cancer Foundation of the People's Republic of China, National Key Research and Development Program.
Abstract (Originalsprache)
Background
Anaplastic lymphoma kinase ( ALK ) test in advanced non‐small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring ALK gene rearrangement. This study aimed to investigate the real‐world test patterns and positive rates of ALK gene rearrangements in advanced NSCLC.
Methods
In this real‐world study (ChiCTR2000030266), patients with advanced NSCLC who underwent an ALK rearrangement test in 30 medical centers in China between October 1, 2018 and December 31, 2019 were retrospectively analyzed. Interpretation training was conducted before the study was initiated. Quality controls were performed at participating centers using immunohistochemistry (IHC)‐VENTANA‐D5F3. The positive ALK gene rearrangement rate and consistency rate were calculated. The associated clinicopathological characteristics of ALK gene rearrangement were investigated as well.
Results
The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma. The quality control analysis of IHC‐VENTANA‐D5F3 revealed an intra‐hospital consistency rate of 98.2% (879/895) and an inter‐hospital consistency rate of 99.2% (646/651). IHC‐VENTANA‐D5F3 was used in 53.6%, real‐time polymerase chain reaction (RT‐PCR) in 25.4%, next‐generation sequencing (NGS) in 18.3%, and fluorescence in‐situ hybridization (FISH) in 15.9% in the adenocarcinoma subgroup. For specimens tested with multiple methods, the consistency rates confirmed by IHC‐VENTANA‐D5F3 were 98.0% (822/839) for FISH, 98.7% (1,222/1,238) for NGS, and 91.3% (146/160) for RT‐PCR. The overall ALK gene rearrangement rates were higher in females, patients of ≤ 35 years old, never smokers, tumor cellularity of > 50, and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup (all P < 0.05).
Conclusions
This study highlights the real‐world variability and challenges of ALK test in advanced NSCLC, demonstrating a predominant use of IHC‐VENTANA‐D5F3 with high consistency and distinct clinicopathological features in ALK ‐positive patients. These findings underscore the need for a consensus on optimal test practices and support the development of refined ALK test strategies to enhance diagnostic accuracy and therapeutic decision‐making in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
- Department of Pathology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
- Department of Pathology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, P. R. China.
- Department of Pathology, Cancer Hospital Affiliated to Shanxi Medical University, Shanxi Province Cancer Hospital, Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, Shanxi, P.…
- Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, P. R. China.
- Department of Pathology, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
ORCID-Profile: Lin Li, Nanying Che, Xueshan Qiu, Zhihong Zhang
Förderung
- CAMS Innovation Fund for Medical Sciences
- Beijing Hope Run Special Fund of Cancer Foundation of the People's Republic of China
- National Key Research and Development Program
- Capital's Funds for Health Improvement and Research
- National Key Research and Development Program of China
Zitieren
APA
Li, L., Li, W., Wu, C., Xi, Y., Guo, L., Ji, Y., Jiang, L., Li, J., Yun, J., Chen, G., Li, Y., Liu, Y., Mu, D., Han, Y., Sun, L., Xia, Q., Teng, X., Che, N., Wu, W., …, & Ying, J. (2024). Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study. Cancer Communications, 44(9), 992-1004. https://doi.org/10.1002/cac2.12593
Vancouver
Li L, Li W, Wu C, Xi Y, Guo L, Ji Y, et al. Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study. Cancer Communications. 2024;44(9):992-1004. doi:10.1002/cac2.12593
BibTeX
@article{Li2024,
author = {Li, Lin and Li, Wencai and Wu, Chunyan and Xi, Yanfeng and Guo, Lei and Ji, Yuan and Jiang, Lili and Li, Ji and Yun, Jingping and Chen, Gang and Li, Yuan and Liu, Yueping and Mu, Dianbin and Han, Yuchen and Sun, Leina and Xia, Qingxin and Teng, Xiaodong and Che, Nanying and Wu, Wei and Qiu, Xueshan and Liu, Chao and Yan, Xiaochu and Li, Daiqiang and Zhang, Zhihong and Wang, Zhe and Li, Yujun and Wang, Zheng and Guo, Lingchuan and Nie, Xiu and Geng, Jingshu and Zhou, Jianhua and Ying, Jianming},
title = {Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study},
journal = {Cancer Communications},
year = {2024},
volume = {44},
number = {9},
pages = {992--1004},
doi = {10.1002/cac2.12593}
}
EUVIMED